Topical Nanosponge Gel For Immunosuppressive Agent

Authors

  • Chodvadiya Chandrika Upendra, Dr. Akruti S. Khodakiya, Dr. Nizant Oza, Dobariya Vithal Dhirubhai, Radadia Ashwinbhai Arjanbhai, Darji Yogeshkumar Govindbhai, Bhumi Patel

DOI:

https://doi.org/10.47750/pnr.2023.14.S01.119

Abstract

Two new topical immunosuppressive treatments, pimecrolimus and tacrolimus, were developed to provide alternatives to topical corticosteroids without the associated adverse events. They work by inhibiting calcineurin in the skin, which regulates the activity of several transcription factors that control cell division and trigger the early stages of T cell activation. Topical tacrolimus inhibits experimentally induced allergic contact dermatitis, and preliminary studies have suggested that the drug is effective in the treatment of atopic dermatitis.

Downloads

Published

— Updated on 2023-01-25

Issue

Section

Articles

How to Cite

Topical Nanosponge Gel For Immunosuppressive Agent. (2023). Journal of Pharmaceutical Negative Results, 855-859. https://doi.org/10.47750/pnr.2023.14.S01.119